Insmed (NASDAQ:INSM) is an early-stage biotech company focused on the development and commercialization of a game-changer inhaled antibiotic treatment for patients battling serious lung diseases. Its lead product candidate is ARIKACE, an inhaled antibiotic designed to reach directly to the site of serious lung infections.
Insmed's share price is currently hovering around $10.50, and I believe ~70% upside from here is a strong possibility over the medium term. In a public offering of its shares a month ago, the company fixed the share price exactly at this level.
Insmed is primarily engaged in the development and commercialization of ARIKACE (liposomal amikacin for inhalation), which is engineered to deliver a proven and potent anti-infective to improve the
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|